Comparison between weekly versus 3-weekly paclitaxel in combination with carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer.
CONCLUSION: There was no difference between both regimens in terms of NAC response and survival outcomes. However, ddPC group showed higher hematologic toxicity requiring dose reduction.
PMID: 31912678 [PubMed - as supplied by publisher]
Source: Journal of Gynecologic Oncology - Category: OBGYN Tags: J Gynecol Oncol Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Hematology | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | OBGYN | Ovarian Cancer | Ovaries | Statistics | Study | Toxicology